GlassScriptPhysician profile
Aliya U Khan
NPI 1487638870
$2,321.55
in general payments reported to CMS, 2019-2025
29 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $278 · 2021: $65.54 · 2022: $60.75 · 2023: $152 · 2024: $310 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,527.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $649.53 | 2019-2025 | |
| Amgen INC. | $350.42 | 2019-2025 | Tavneos, Uplizna, Krystexxa |
| Novartis Pharmaceuticals Corporation | $217.37 | 2019-2025 | |
| Janssen Biotech, INC. | $142.66 | 2019-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $135.36 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $86.68 | 2021-2024 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $85.76 | 2019-2025 | Orencia |
| Actelion Pharmaceuticals US, INC. | $68.98 | 2020 | |
| Horizon Therapeutics Plc | $65.27 | 2019-2021 | |
| Csl Behring | $64.66 | 2023-2025 | Hizentra, Haegarda, Andembry |
| Organon LLC | $51.20 | 2024-2025 | Renflexis, Hadlima |
| Sanofi-Aventis U.S. LLC | $39.67 | 2019 | |
| Ucb, INC. | $34.74 | 2020-2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $30.66 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $26.14 | 2025 | Jubbonti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.00 | 2024 | Ofev |
| Depuy Synthes Sales INC. | $24.35 | 2024 | Orthovisc, Monovisc |
| Invivyd INC | $23.16 | 2025 | Pemgarda |
| Sobi, INC | $22.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.63 | 2019 | |
| Genentech USA, INC. | $19.98 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.98 | 2024 | Acthar |
| Genzyme Corporation | $19.60 | 2025 | |
| Fresenius Kabi USA, LLC | $19.03 | 2023 | |
| Glaxosmithkline, LLC. | $14.11 | 2020 | |
| Merck Sharp & Dohme LLC | $11.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.60 | 2019 | |
| Radius Health, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliya Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.